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Given the established individual activity of docetaxel and ifosfamide in anthracycline pretreated advanced breast cancer, the present
phase I–II study aimed to define the maximum tolerated dose (MTD), the dose-limiting toxicities (DLTs), and activity of the
docetaxel–ifosfamide combination in this setting. Cohorts of three to six patients with histologically confirmed metastatic breast
cancer after prior anthracycline-based chemotherapy were treated at successive dose levels (DLs) with escalated doses of docetaxel
70–100mgm
 2 over 1h on day 1 followed by ifosfamide 5–6gm
 2 divided over days 1 and 2 (2.5–3.0gm
 2day
 1 over 1h), and
recycled every 21 days. G-CSF was added once dose-limiting neutropenia was encountered at a certain DL and planned to be
incorporated prophylactically in subsequent higher DLs. In total, 56 patients with a median age of 54.5 (range, 32–72) years and
performance status (WHO) of 1 (range, 0–2) were treated at five DLs as follows: 21 in phase I DLs (DL1: 3, DL2: 6, DL3: 3, DL4: 6,
and DL5: 3) and the remaining 35 were treated at DL4 (total of 41 patients at DL4), which was defined as the level for phase II
testing. All patients were assessable for toxicity and 53 for response. Dose-limiting toxicity (with the addition of G-CSF after DL2)
was reached at DL5 with two out of three initial patients developing febrile neutropenia (FN). Clinical response rates, on an
intention-to-treat basis, in phase II were: 53.6% (95% CI, 38.3–68.9%); three complete remissions, 19 partial remissions, seven stable
disease, and 12 progressive disease. The median response duration was 7 months (3–24 months), median time to progression 6.5
month (0.1–26 month), and median overall survival 13 months (0.1–33 months). Grade 3/4 toxicities included time to progression
neutropenia in 78% of patients–with 63% developing grade 4 neutropenia (p7 days) and in 12% of these FN, while no grade 3/4
thrombocytopenia was observed. Other toxicities included peripheral neuropathy grade 2 only in 12%, grade 1/2 reversible CNS
toxicity in 17%, no renal toxicity, grade 2 myalgias in 10%, grade 3 diarrhoea in 10%, skin/nail toxicity in 17%, and grade 2 fluid
retention in 2% of patients. One patient in the study treated at phase II died as a result of acute liver failure after the first cycle. In
conclusion, the present phase I–II study determined the feasibility of the docetaxel–ifosfamide combination, defined the MTD and
demonstrated the encouraging activity of the regimen in phase II, thus warranting further randomised phase III comparisons to single-
agent docetaxel or combinations of the latter with other active agents.
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Docetaxel represents a novel antimicrotubule agent that promotes
the polymerisation of tubulin and thereof stabilises microtubules
by preventing their disassembly. Docetaxel (Taxotere
s) has
demonstrated a broad spectrum of activity against a variety of
advanced solid tumours, and breast cancer represents the first in
which docetaxel has been successfully tested (Salminen et al, 1999).
In particular, for patients with prior anthracycline-based therapy,
taxanes represent the treatment of choice in the salvage setting,
since previously applied agents have demonstrated inferior
activity, taxanes have exhibited a relative lack of cross-resistance
with anthracyclines, and have so far demonstrated fair tolerability
in pretreated patients.
Three second-line phase III studies in anthracycline-refractory
patients evaluated single-agent docetaxel vs salvage regimens
thought to be active in this setting, namely mitomycin-C+vinblas-
tine (Nabholtz et al, 1999), methotrexate–5-fluorouracil (5-FU)
(Sjostrom et al, 1999), and infusional 5-FU+vinorelbine (Monnier
et al, 1998). Two of the above studies (Nabholtz et al, 1999;
Sjostrom et al, 1999) demonstrated an advantage in favour of
docetaxel with respect to response rate (RR) and time to
progression (TTP), while only the study of Nabholtz et al (1999)
so far reported a significant 3-month prolongation in median
overall survival (OS), while, in contrast, the third study by
Monnier et al (1998) did not report any advantage of docetaxel vs
infusional 5-FU+vinorelbine. Moreover, in a recently reported
large phase III randomised trial (Chan et al, 1999) comparing
single-agent docetaxel vs doxorubicin in alkylating agent pre-
treated metastatic breast cancer patients reported a significantly
higher RR for docetaxel (52 vs 37%), without, however, prolongation
in median TTP. The other taxane, paclitaxel, has been compared to
doxorubicin in two recent large phase III studies (Sledge et al,
1997; Paridaens et al, 2000). The first study conducted by the
Received 30 April 2002; revised 5 December 2002; accepted 22 January
2003
*Correspondence: Dr C Kosmas; E-mail: ckosm@ath.forthnet.gr
British Journal of Cancer (2003) 88, 1168–1174
& 2003 Cancer Research UK All rights reserved 0007– 0920/03 $25.00
www.bjcancer.com
C
l
i
n
i
c
a
lEORTC yielded significantly higher RRs and longer progression-
free survival in favour of doxorubicin (Paridaens et al, 2000). The
second study, a three-arm North American trial, yielded equivalent
results in terms of RR, TTP, and OS between the doxorubicin and
paclitaxel single-agent arms (Sledge et al, 1997).
Ifosfamide, an oxazophosphorine alkylating agent like cyclopho-
sphamide, has demonstrated substantial activity in advanced
breast cancer (Ahmann et al, 1974). The rationale for combining
docetaxel and ifosfamide derives from in vitro data indicating the
ability of taxanes to revert the repair mechanisms responsible for
the development of resistance to alkylating agent-induced DNA
damage. A single previous phase I study has evaluated the
feasibility of the docetaxel–ifosfamide combination without G-CSF
in pretreated patients with a variety of advanced solid tumours.
Dose-limiting toxicity (DLT) was reached at docetaxel 85mgm
 2
on day 1 followed by ifosfamide 5gm
 2 administered as 24-h
infusion and the recommended phase II doses were docetaxel
75mgm
 2+ifosfamide 5gm
 2 (Pronk et al, 1998).
Given the encouraging activity of each individual cytotoxic
agent and the feasibility of the docetaxel+ifosfamide combination,
we elected to conduct a phase I/II study in an attempt to further
intensify the above regimen, possibly with the aid of G-CSF, in
patients with anthracycline-pretreated metastatic breast cancer
and administer it in a total outpatient setting by avoiding the 24-h
infusion and selecting the fractionated short-over 2 d-infusion of
ifosfamide.
PATIENTS AND METHODS
Patient selection
Patients with histologically confirmed stage IV breast cancer
pretreated with anthracycline-based chemotherapy were enrolled;
patients progressing on anthracycline-based therapy or within 4
months after the end of such a treatment or patients treated with
neoadjuvant and adjuvant anthracyclines that progressed within 12
months after the end of adjuvant chemotherapy were deemed
anthracycline-refractory, while all other patients were considered
potentially anthracycline-sensitive. Patients had to have bidimen-
sionally measurable lesions with at least one outside a previously
irradiated field, unless definite evidence of progression at this site
was observed during a minimum 3-month period. No prior
taxanes or ifosfamide were allowed. Other inclusion criteria were
as follows: age 18–72 years; a World Health Organization (WHO)
performance status (PS) of 0–2; life expectancy of at least
3 months; adequate haematopoietic (ANCX1500ml
 1, PLT
X100000ml
 1), liver (bilirubin o1.5mgdl
 1, AST/ALT
o2 upper normal limit, unless caused by tumour and serum
albumin 43.0gdl
 1) and renal function (BUN and creatinine
o1.5  upper normal limit; and creatinine clearance
450mlmin
 1), and cardiac function (left ventricular ejection
fraction (LVEF) X50%). Patients with brain metastases were
eligible provided that they had been irradiated and had clinical and
radiological improvement and were off steroids or receiving
tapering doses of steroids. Other exclusion criteria were radiation
therapy within 4 weeks from treatment initiation, irradiation of
more than 25% of the bone marrow-bearing skeleton, severe
infection or malnutrition. The study was approved by the Ethical
and Scientific Committees of the participating institutions and
informed consent was obtained from each patient before study
entry.
Treatment schedule
Eligible patients were entered in the dose levels (DLs) as shown
in Table 1. Docetaxel (Taxotere
s) was administered at
70–100mgm
 2 over 1-h by i.v. infusion on day 1, after
premedication consisting of dexamethasone 20mg, dimethidene
maleate (Fenistil
s) 4mg and ranitidine 50mg; all administered i.v.
30min before docetaxel. Ifosfamide followed docetaxel and was
administered at 5.0–6.0gm
 2 divided over 2 days (2.5–3.0gm
 2
day
 1 i.v. over 1h) together with mesna uroprotection adminis-
tered at 40% of the ifosfamide dose, together with ifosfamide
within the same solution (1l of 1/2 (0.9% normal saline+dextrose
5%)+20meq KCl+30meq bicarbonate and 10mg furosemide), and
80% of the ifosfamide dose divided within the postifosfamide
hydration fluids, which consisted of 2l (1/2 (0.9% normal
saline+dextrose 5%)+20meq KCl+ 10mg furosemide) adminis-
tered over 6h in the outpatient unit.
Supportive care
Standard antiemetic medication included ondansetron 24mg i.v.
1-h before chemotherapy on days 1, 2 and postchemotherapy 8mg
t.i.d. per os on days 3–5. Dexamethasone 20mg i.v. was
administered 1-h before chemotherapy (on day 1 as docetaxel
premedication as well) on days 1, 2 and postchemotherapy 4mg
t.i.d. or methylprednisolone 16mg b.i.d per os on days 3–5.
Haematopoietic growth factors included G-CSF (lenograstim)
150mgm
 2day
 1 s.c. from day 4 until day 10 or until
WBCX10000ml, whatever came first.
Dose escalation schedule, DLTs, and dose modifications
Dose-limiting toxicities were assessed during the first chemother-
apy cycle and were considered to have been reached when one of
the following was met: (i) grade 4 neutropenia of 47 days
duration, (ii) any episode of Xgrade 3 febrile neutropenia, (iii) any
episode of grade 4 thrombocytopenia, (iv) any nonhaematologic
grade 3 or 4 toxicity excluding nausea/vomiting, musculoskeletal-
arthritic pain, and alopecia.
Cohorts of three patients were entered at the dose levels shown
in Table 1. In the case that DLT was encountered (defined above)
in one out of three patients at a certain DL a total of six patients
were entered at that particular level and if more than two out of six
(33%) met the DLT requirements (in total at least three out of six
patients developed the same DLT) no further accrual to the next
higher DL was undertaken and the level immediately before the
DLT was considered as the maximum tolerated dose (MTD). In the
case that two out of the first three patients at a certain level
experienced the same DLT, no more patients were accrued at that
level and further dose escalation was stopped. The DL immediately
before the one that DLT was reached, that is, the MTD, was
recommended for further phase II testing.
The following guidelines were applied with respect to dose
reductions for toxicity: (i) for neutropenia and thrombocytopenia,
meeting the aforementioned criteria, docetaxel and ifosfamide
doses were reduced by 20% in subsequent cycles and if toxicity
reappeared after a total of 40% reduction from the starting dose in
Table 1 Docetaxel–ifosfamide dose levels in the phase I part of the
study
Drug doses
Dose
level
Docetaxel
(mgm
 2)
Ifosfamide
(gm
 2) G-CSF
No. of patients
entered
1 70 5.0   3
2 85 5.0   6
3 85 5.0 + 3
4 100 5.0 + 6+35 (phase II)
5 100 6.0 + 3
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was evaluable for toxicity and response, (ii) for Xgrade 3
mucositis, the doses of docetaxel and ifosfamide were reduced
by 20% in subsequent cycles, (iii) for neuropathy Xgrade 3
treatment was interrupted, and (iv) for renal toxicity Xgrade 3
toxicity (serum creatinine elevations43 normal) treatment was
withheld until recovery (serum creatinine o1.8mgdl
 1) with
ifosfamide administered with more posthydration and hospitalisa-
tion in subsequent cycles. If grade 3 or more renal toxicity
persisted, ifosfamide was omitted in subsequent cycles. (v) For
Xgrade 3 CNS toxicity (ifosfamide encephalopathy), the dose of
ifosfamide was reduced by 20% and more hydration with
bicarbonates was anticipated in subsequent cycles. In the case
that encephalopathy reappeared, then ifosfamide was omitted from
subsequent cycles. In the case that blood counts had not recovered
to ANCX1500ml
 1 and PLTX100000ml
 1 on the day of therapy,
treatment was withheld until recovery, and after a maximum delay
of 2 weeks (day 35) no further therapy was administered in case
that counts did not return to normal.
Patient evaluation
Baseline evaluations included: patient history, physical examina-
tion, chest X-rays, complete blood count with differential and
platelet count, blood chemistry (AST, ALT, sALP, gamma-GT,
bilirubin (direct/indirect), protein, creatinine, BUN, uric acid,
glucose, Na
+,K
+,C a
2+,P
 ), ECG, and echocardiography or
multigated angiogram (MUGA) scan with LVEF measurement.
Computed tomography (CT) scans of the chest, abdomen, pelvis,
and bone scintigraphy were performed at study entry and CT scan
of the brain whenever clinically indicated. Complete blood counts
with differential and platelet counts were performed twice weekly
or daily in case of grade 3/4 neutropenia, thrombocytopenia or
febrile neutropenia until haematologic recovery; blood chemistry
and physical examination were performed every 3 weeks.
Toxicities were evaluated according to the NCI common toxicity
criteria (NCI-CTC).
Responses (complete remission (CR), partial remission (PR),
stable disease (SD), and progressive disease (PD)) were evaluated
according to WHO response criteria (Miller et al, 1981).
Patients were evaluated before each cycle for lesions assessable
by physical examination or chest X-ray; however, all patients were
evaluated by the appropriate imaging studies indicative of the
measurable target lesions every three chemotherapy cycles.
Patients with disease regression or stabilisation received up to
six chemotherapy cycles. Patients with PD were withdrawn from
the study. The duration of response was measured from the first
documentation of response to disease progression.
Statistical analysis
Patients were evaluated for response on an intention-to-treat basis,
and patients who received at least one cycle of treatment were
evaluable for toxicity. Toxicity and DLT analyses were carried out
regarding patients entering the phase I evaluation, and after the
recommended level for phase II testing was defined, analysis of
toxicity in the phase II part of the study was carried out separately.
Response duration was measured from the day of its initial
documentation until confirmed disease progression; TTP was
calculated from study entry until evidence of PD; OS was measured
from the day of entry until last follow-up or death. In the phase II
part of the study, the 95% confidence intervals (CI) for RRs were
calculated from the binomial distribution (Simon, 1986). Median
duration of response, median TTP, and actuarial OS were
estimated by the product-limit method of Kaplan–Meier (Kaplan
and Meier, 1959). According to the two-stage design reported by
Simon (1989) for phase II studies, with an expected RR of 50% and
a worst RR of 30%, 28 patients would be required in the first step.
If a minimum of seven responses were encountered, a total of 39
patients would be accrued (min–max design). Thereby, the
probability of accepting a therapy with a real RR less than 30%
and the risk of rejecting a treatment with a RR greater than 50%
would be in both cases less than 10%.
RESULTS
Patient characteristics
A total of 56 patients were entered in the present phase I–II study
of docetaxel–ifosfamide combination between March 1997 and
November 2000. Patients were entered at five consecutive DLs in
the phase I part of the study (Table 1) as follows: 21 were treated in
phase I DLs (DL1: 3, DL2: 6, DL3: 3, DL4: 6, and DL5: 3) and the
remaining 35 were treated at DL4, which was defined as the level
for phase II testing. In total, 41 patients were treated at DL4 that
was defined as the MTD (see below). Patients characteristics are
demonstrated in Table 2. All patients were evaluable for toxicity
Table 2 Patient characteristics
Characteristic No. %
Total patients 56 100
Age (years)
Median 54.5
Range 32–72
Performance status (WHO)
0–1 48 86
28 1 4
Menopausal status
Premenopausal 20 36
Postmenopausal 36 64
Histology
Ductal 42 75
Lobular 5 9
Not specified 9 16
Hormone receptors
ER /PR  13 23
ER+/PR  10 18
ER+/PR+ 20 36
ER /PR+ 7 12
Not done 6 11
No. of prior regimens
13 0 5 3
22 4 4 3
32 4
Type of chemotherapy
Adjuvant CAF 7 12.5
Neoadjuvant 7 12.5
Metastatic disease 24 43
Adjuvant+metastatic 18 32
Anthracycline sensitivity
Sensitive 23 39
Refractory 33 61
Metastatic sites
13 0 5 3
24 3 4 3
X32 4
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for response in the phase II part of the study. The median age was
54.5 (range, 32–72) years, the median WHO performance status
was 1 (range, 0–2); being 0–1 for 48 (86%) patients. In all, 33
(59%) patients were anthracycline-refractory and 23 (41%) were
potentially anthracycline-sensitive according to the definitions.
The median number of prior chemotherapy regimens including
adjuvant and/or anthracycline-based treatment was 1 (range, 1–3).
The median interval from the end of the last chemotherapy
regimen was 6 (range, 1.5–45) months. All patients received at
least one chemotherapy cycle and were therefore evaluable for
toxicity, while 53 out of 56 patients received at least two
chemotherapy cycles and were therefore evaluable for response.
Dose-limiting toxicity was reached at DL5 with two out of three
initial patients developing febrile neutropenia.
Toxicities
Phase I Five DLs were evaluable for toxicity in the phase I part of
the current study. No DLTs were observed at DL1. At DL2, three
out of six patients developed febrile neutropenia after the first
cycle. The same DL was repeated with the addition of prophylactic
G-CSF as DL3, and none of the three patients entered developed
DLT. At DL4, one out of six patients entered developed febrile
neutropenia. At DL5, two our of three initial patients developed
febrile neutropenia and one of these developed sepsis and grade 3
diarrhoea managed successfully by broad-spectrum antibiotics and
other supportive care measures; neither further accrual of patients
was undertaken nor further dose escalation was attempted beyond
DL5 according to our preset definitions. No other important
haematologic or nonhaematologic grade 3/4 DLT was observed in
phase I (Table 3).
Phase II Haematologic and nonhaematologic toxicities encoun-
tered in the present study were evaluated in all the patients
and cycles and are shown in Tables 4 and 5, respectively. In brief,
grade 3/4 toxicities included neutropenia 32 out of 41 (78%)–with
26 out of 41 (63%) developing grade 4 neutropenia (p7 days)
and five of these febrile neutropenia (12%). All were managed
successfully with broad-spectrum antibiotics. One patient
with extensive liver metastases but no pretreatment deterioration
of liver function (according to the eligibility criteria) developed
severe metabolic acidosis, uric acid, liver enzyme, and bilirubin
elevation 16h after the first dose of docetaxel and ifosfamide
and died as a result of that complication 48h later from multiorgan
failure; her death could be attributed to either drug-related
hepatic toxicity or acute tumour lysis syndrome, or a combination
of all these factors. No other treatment-related deaths were
observed. No grade 3 or 4 thrombocytopenia was observed.
Anaemia was cumulative in nature and six out of 41 patients
required packed red blood cell transfusions for grade 3 anaemia.
Other nonhaematologic toxicities are shown in detail in Table 5.
One patient developed grade 1 and one grade 3 pulmonary
toxicity, after the fifth and fourth cycle of treatment, respectively.
The latter patient developing grade 3 pulmonary toxicity
with diffuse alveolar infiltrates and hypoxaemia improved rapidly
after reinstitution of steroids, but further treatment was
witheld.
Compliance to treatment
In phase I part of the study, six patients who developed DLTs
continued with 20% dose reduction (see Table 3 also).
In phase II (including all patients entered at DL4), a total
of 190 treatment cycles were administered; median: 6 (range: 1–6),
with a mean of 4.6 cycles per patient. In total, 16 patients
did not complete the planned six cycles because of the following
reasons: 12 patients (one after cycle 1, seven after cycle 2, and
four after cycle 3) because of PD; one because of toxic death
(liver failure) after cycle 1, and three after cycle 4 because of
personal choice; two patients and grade 2 asthenia/fatigue; one
patient. A total of 13 treatment cycles (7%) were delayed for
2–14 days (median: 7 days) for the following reasons: patient’s
own choice or logistic reasons of travelling from district areas;
seven cycles, transfusion for Grade 2/3 anaemia; four cycles,
neutropenia (with neutrophils o1500ml
 1) on the day of
treatment; two cycles.
Dose-intensity analysis
The administered median dose intensities for each drug of the
docetaxel/ifosfamide combination in the phase II part of the study
were as follows: for docetaxel 30.75mgm
 2 week
 1 (range: 24.2–
33.3), and for ifosfamide 1.54gm
 2 week
 1 (range: 1.24–1.67),
that is, 92% (range: 72.6–100%) of the planned dose intensities for
both drugs.
Response to treatment and survival
In total, 53 patients were assessable for response when both phase I
and II parts of the study (all DLs) were considered. Overall, five
CRs and 24 PRs were recorded, for a 52% (95% CI: 39–65%) RR on
intention to treat (see also Table 6). When RRs were divided
according to prior anthracycline sensitivity; 13 out of 23 (56.5%;
95% CI, 34.5–76.8%) of anthracycline-sensitive patients vs 16 out
of 33 (48.5%; 95% CI, 30.8–66.5%) of anthracycline-resistant
patients responded, and the difference did not reach significance.
Overall, median duration of response was 7 (3–24) months,
median TTP 6 (0.1–26) months, and median OS 12 (0.1–33)
months. Median duration of response, median TTP, and median
OS for anthracycline-sensitive patients were: 9 (3–24), 6.5 (0.2–
26), and 13 (1–33) months, respectively, while for anthracycline-
refractory patients these were: 6.5 (3–14+), 5 (0.1–16), and 12
(0.1–25+) months, respectively.
Clinical RRs, on an intention-to-treat basis, in phase II (MTD)
were as follows: 22 out of 41 (53.6%; 95% CI, 38.3–68.9%)
Table 3 Results of docetaxel–ifosfamide dose escalation in phase I
DL
No. of
patients
No. of
treatment
cycles DLT Type of toxicity (Grades 3 and 4)
1 3 18 0/3 None
2 6 29 3/6 3 Gr4 FN
3 3 15 0/3 None; Gr4 neutropenia of o 7 days duration in one patient
4 6 32 1/6 1 Gr4 FN
5 3 16 2/3 2 Gr4 FN; (one of these with sepsis and Gr3 diarrhoea)
DL=dose level, DLT=dose-limiting toxicity (after first cycle), FN=febrile neutropenia.
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(Table 6). Again, no difference in RRs was observed between
anthracycline-sensitive and anthracycline-refractory patients.
The patient who died as a result of toxicity and the patient with
rapid progression, both after the first cycle were considered as
having PD. The median response duration was 7 (3–24) months,
median TTP 6.5 (0.1–26) months, and median OS 13 (0.1–33)
months.
DISCUSSION
The rationale for combining taxanes paclitaxel or docetaxel with
ifosfamide derives from both in vitro data and theoretical
assumptions based on the properties of each individual cytotoxic
agent to mediate its cellular damage. Most in vitro data exist with
paclitaxel. In brief, paclitaxel inhibits the energy-dependent
enzymatic reactions, by disengaging activated intracellular phos-
phate (e.g. ATP and GTP), required for the repair of the DNA
damage induced by alkylating agents (prevention of DNA strand
separation and unwinding) (Reed et al, 1995). In vitro synergism
has been demonstrated between paclitaxel and hydroperoxy-
ifosfamide, an activated ifosfamide metabolite, against cisplatin-
sensitive and -resistant Ovarian Carcinoma cell lines when
paclitaxel preceded hydroperoxy-ifosfamide or during concurrent
exposure (Liebmann et al, 1994; Klaassen et al, 1996).
Based on these preclinical in vitro experimental data, we believe
that the sequence and infusion times regarding docetaxel and
ifosfamide, as applied in the present study, might lead to potential
in vivo synergism between these two drugs (Kearns et al, 1995).
Moreover, our prior experience with paclitaxel–ifosfamide–
cisplatin (Kosmas et al, 2000a,b; 2001) or docetaxel–ifosfa-
mide–cisplatin (Kosmas et al, 2002) combinations has demon-
strated their feasibility in phase I and phase II studies in advanced
solid tumours and lung cancer in particular.
If the above considerations regarding sequence-dependent
interactions for optimal drug scheduling are important in order
to maximise efficacy, of equal importance are the effects of drug
sequencing related to bone marrow toxicity. Data from phase I
clinical studies of the paclitaxel/cyclophosphamide combination
employing different schedules of drug administration demon-
strated variable haematologic toxicity. The highest degree of
haematologic toxicity was encountered when paclitaxel was
administered by 24-h or 72-h continuous infusion with high doses
of cyclophosphamide (Kennedy et al, 1996; Tolcher et al, 1996).
However, when paclitaxel, given by 3-h infusion, was followed by
cyclophosphamide, bone marrow toxicity was of much less severity
(Pagani et al, 1997). In contrast, with the docetaxel–ifosfamide
combination, the schedule of administering the taxane first led to
less haematologic toxicity and a higher MTD than did the reverse
drug sequence (Pronk et al, 1998). It is therefore realistic to
consider that the sequence of administration of docetaxel followed
by ifosfamide could account for the tolerable haematologic
toxicity, that is, neutropenia and thrombocytopenia, encountered
in our study up to high individual drug doses that were achieved at
DL4. Moreover, as grade 4 neutropenia and febrile neutropenia
represented the only significant toxicities in our study, the 12%
incidence of the latter appears rather low and compares favourably
to that of single agent docetaxel at 100mgm
 2 with G-CSF
support. The phase I study of Pronk et al (1998) that has evaluated
the feasibility of the docetaxel–ifosfamide combination without G-
CSF in pretreated patients with a variety of advanced solid
tumours determined the DLT of the combination being mainly
neutropenia at the following doses; docetaxel 85mgm
 2 on day 1
followed by ifosfamide 5gm
 2 administered as 24-h infusion, and
the recommended phase II doses were docetaxel 75mgm
 2
+ifosfamide 5gm
 2 (Pronk et al, 1998). A subsequent pharmaco-
kinetic analysis of the regimen by the same investigators found
that the sequence of drug administration did not affect the
clearance and the area under the curve (AUC) of docetaxel.
However, there was a decrease in the AUC of ifosfamide in the
schedule of docetaxel-ifosfamide compared with the reverse
sequence (Schrijvers et al, 2000). It is also possible that ifosfamide
might yield a decreased AUC when administered by 24-h
continuous infusion compared to short 1–2-h infusions fractio-
nated over 2 or more days (Cerny et al, 1999).
Ifosfamide combinations in advanced anthracycline-pretreated
breast cancer have been applied in recent years. Combination of
Table 4 Haematologic toxicities (NCI-CTC grade) (phase II part of the
study)
NCI-CTC grade (% of patients, all cycles)
Toxicity 01234
Leukopenia 11 4 4 46 35
Neutropenia 11 0 11 15 63
Thrombocytopenia 58 32 10 0 0
Anaemia 5 25 55 15 0
Febrile neutropenia 12%
Table 5 Nonhaematologic toxicities (NCI-CTC grade) (phase II part of
the study)
NCI-CTC grade (% of patients, all cycles)
Toxicity 0 1 2 3 4
Nausea and vomiting 54 27 14 5 0
Mucositis 37 37 22 0 0
Myalgia/arthralgia 61 24 15 0 F
Neurologic
Peripheral 32 54 14 0 0
CNS 59 22 17 0 2
Infection 97.5 2.5 0 0 0
Diarrhoea 41 37 12 10 F
Hypersensitivity reactions 93 7 0 0 0
Alopecia 0 0 100 0 F
Skin/nail 41.5 41.5 17 0 0
Fluid retention 61 37 2 0 F
Asthenia/fatigue 27 41.5 22.5 10 F
Cardiac 100 0 0 0 0
Pulmonary 96 2 0 2 0
Renal 97.5 0 0 2.5 0
Haematuria 98 2 0 0 0
Table 6 Response to docetaxel–ifosfamide (all levels); n=56 patients
No. of
assessable
No. of responses
DL patients CR PR SD PD ORR (%)
13 1 0 1 1 3 3
26 0 3 2 1 5 0
33 1 1 1 0 6 7
4 (phase II) 41 3 19 7 12 53.6
53 0 1 1 1 3 3
Total 56 5 24 12 15 52
ORR=overall response rate.
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lifosfamide with vinorelbine demonstrated an RR of 56% in a group
of patients with no or minimally pretreated metastatic breast
cancer (Leone et al, 1996). The combination of a fixed dose of
doxorubicin 20mgm
 2 3 days with escalating doses of ifosfa-
mide (1.2–2.75gm
 2day
 1 5 days) with G-CSF support in a
phase I study focusing in stage IV chemotherapy-naı ¨ve breast
cancer has yielded the feasibility of a quite high dose of ifosfamide
12.5gm
 2 (total) with an RR of 83% of which 33% were CRs
(Bitran et al, 1995).
Moreover, ifosfamide has been combined with paclitaxel in a
phase I study in patients with advanced heavily pretreated
predominantly breast and ovarian malignancies including
13 patients with advanced anthracycline-pretreated breast cancer
(Bunnell et al, 1998). While the MTD reached for paclitaxel
was 190mgm
 2 by 24-h infusion and for ifosfamide 3.0gm
 2day
 1
for 3 days (total dose: 9.0gm
 2), no major toxicities were en-
countered with this quite high dose of ifosfamide administered
by short noncontinuous daily infusion, while RRs in breast cancer
patients were almost 62% with 31% CRs in this study (Bunnell
et al, 1998).
Another phase II study evaluating docetaxel and ifosfamide in
women with heavily pretreated anthracycline- and hormone-
refractory breast cancer led to early disappointment in view of
no responses seen in the first 10 patients entered (Lorusso et al,
2000).
In the aforementioned phase I–II study of Pagani et al (1997)
evaluating the paclitaxel/cyclophosphamide doublet, a dose–
response effect was suggested for pretreated patients, with a lower
RR reported for those receiving o1500mgm
 2 of cyclopho-
sphamide (Pagani et al, 1997). As equivalent cytotoxic alkylator
doses of ifosfamide are anticipated at 4.5–6.0mgm
 2, the
recommended phase II dose derived from our study regarding
ifosfamide might represent an optimal alternative to cyclopho-
sphamide with less haematologic toxicity.
The value of ifosfamide in relapsed anthracycline-pretreated
advanced breast cancer as a single agent or in combination, despite
promising phase II results, cannot currently be defined in the
absence of randomised data. As the combination of docetaxel+
ifosfamide in the phase II part of the present study yielded a 54%
RR, it can be argued that similar results might have been obtained
with single-agent docetaxel. However, the almost 55% RRs
obtained with single-agent docetaxel in the early phase II studies
(Ravdin et al, 1995; Valero et al, 1995) should be regarded as
preliminary, since these have been based in small numbers of
patients and subsequent randomised studies of single-agent
docetaxel vs MMC+VLB or vs MF in anthracycline-refractory or
heavily pretreated patients yielded RRs of 30 and 42%, respec-
tively, for docetaxel (Nabholtz et al, 1999; Sjostrom et al, 1999).
Moreover, it should be emphasised that ours was a dose-finding/
preliminary efficacy phase I–II study, with a 12% incidence of
febrile neutropenia, which is still of concern in the setting of
palliative chemotherapy.
Therefore, randomised phase III studies of single-agent
docetaxel at 100mgm
 2 vs the combination of docetaxel+ifosfa-
mide, as defined in the present study, might address the value of
adding ifosfamide to docetaxel, as well as the issue of cost
effectiveness of such a combination, since it is well appreciated
that ifosfamide administration is rather cumbersome, even in the
outpatient setting, expensive and requires multiple admissions
(over 2–5 days) for each cycle. However, it should be kept in mind
that until recently combination chemotherapy has never shown
any clear survival benefit over single agents in randomised trials,
while instead inducing more toxicity in some studies. Recent
results with the docetaxel+oral capecitabine (Xeloda
s) combina-
tion vs single-agent docetaxel in a phase III randomised North
American trial have yielded the superiority and convenience of the
combination in anthracycline pretreated breast cancer (O’Shaugh-
nessy et al, 2002), thus providing a docetaxel combination of more
clinical interest. At present, our results can be viewed as having
defined the MTD, the recommended phase II doses and RR of the
docetaxel+ifosfamide combination, which warrant further rando-
mised phase III comparisons to docetaxel monotherapy or other
active combinations of docetaxel with newer agents, such as
gemcitabine, vinorelbine, or capecitabine.
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